TWI825131B - Htlv-1關聯性脊髓病(ham)之治療或預防劑、及ham之治療方法 - Google Patents
Htlv-1關聯性脊髓病(ham)之治療或預防劑、及ham之治療方法 Download PDFInfo
- Publication number
- TWI825131B TWI825131B TW108125746A TW108125746A TWI825131B TW I825131 B TWI825131 B TW I825131B TW 108125746 A TW108125746 A TW 108125746A TW 108125746 A TW108125746 A TW 108125746A TW I825131 B TWI825131 B TW I825131B
- Authority
- TW
- Taiwan
- Prior art keywords
- rgma
- ham
- cells
- antibody
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018135925 | 2018-07-19 | ||
| JP2018-135925 | 2018-07-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202019482A TW202019482A (zh) | 2020-06-01 |
| TWI825131B true TWI825131B (zh) | 2023-12-11 |
Family
ID=69163691
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108125746A TWI825131B (zh) | 2018-07-19 | 2019-07-19 | Htlv-1關聯性脊髓病(ham)之治療或預防劑、及ham之治療方法 |
| TW112142583A TW202408577A (zh) | 2018-07-19 | 2019-07-19 | Htlv-1關聯性脊髓病(ham)之治療或防預劑、及ham之治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112142583A TW202408577A (zh) | 2018-07-19 | 2019-07-19 | Htlv-1關聯性脊髓病(ham)之治療或防預劑、及ham之治療方法 |
Country Status (16)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2025070749A1 (cg-RX-API-DMAC7.html) * | 2023-09-29 | 2025-04-03 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201710296A (zh) * | 2015-04-28 | 2017-03-16 | Mitsubishi Tanabe Pharma Corp | RGMa結合蛋白質及其使用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1442749A1 (en) * | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| WO2005087268A1 (ja) * | 2004-03-11 | 2005-09-22 | Bioclues, Inc | 軸索再生促進剤 |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| CN102131571B (zh) | 2008-09-02 | 2014-03-05 | 东丽电池隔膜株式会社 | 微孔性高分子膜、该膜的制备方法及该膜作为电池隔膜的应用 |
| JP5552630B2 (ja) | 2008-10-24 | 2014-07-16 | 学校法人 聖マリアンナ医科大学 | Htlv−i関連脊髄症を治療または予防するための医薬、およびhtlv−i関連脊髄症の患者に対する抗体療法の効果を試験する方法 |
| KR102284780B1 (ko) | 2009-12-09 | 2021-08-02 | 미쓰비시 타나베 파마 코퍼레이션 | T 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 t 세포 활성화 저해 물질의 스크리닝 방법 |
| CA2824515C (en) * | 2011-01-18 | 2022-09-13 | Bioniz, Llc | Compositions and methods for modulating gamma-c-cytokine activity |
| JP5963233B2 (ja) * | 2011-12-07 | 2016-08-03 | 学校法人 聖マリアンナ医科大学 | Htlv−1関連脊髄症を治療または予防するための医薬および前記医薬を用いた抗体療法の治療効果の確認方法 |
| JP6310845B2 (ja) * | 2012-07-06 | 2018-04-11 | 学校法人 聖マリアンナ医科大学 | Htlv−1関連脊髄症患者の治療方法および治療剤 |
| WO2016038084A1 (en) | 2014-09-10 | 2016-03-17 | AbbVie Deutschland GmbH & Co. KG | Rgma fragment based diagnostic assay |
| WO2017189963A1 (en) * | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| TW202523689A (zh) * | 2016-06-01 | 2025-06-16 | 美商艾伯維有限公司 | 治療脊髓損傷及疼痛之方法 |
| US10772887B2 (en) * | 2016-08-03 | 2020-09-15 | Kagoshima University | Anti-HTLV-1 drug and therapeutic agent for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) |
-
2019
- 2019-07-19 PE PE2025002847A patent/PE20260298A1/es unknown
- 2019-07-19 CN CN202310983521.2A patent/CN116850291A/zh active Pending
- 2019-07-19 WO PCT/JP2019/028431 patent/WO2020017629A1/ja not_active Ceased
- 2019-07-19 SG SG11202100561QA patent/SG11202100561QA/en unknown
- 2019-07-19 CN CN202310983220.XA patent/CN116942831A/zh active Pending
- 2019-07-19 CN CN201980048012.2A patent/CN112566664B/zh active Active
- 2019-07-19 EP EP25202154.8A patent/EP4656657A3/en active Pending
- 2019-07-19 KR KR1020217005032A patent/KR20210034055A/ko not_active Ceased
- 2019-07-19 JP JP2020531380A patent/JP7150286B2/ja active Active
- 2019-07-19 TW TW108125746A patent/TWI825131B/zh active
- 2019-07-19 TW TW112142583A patent/TW202408577A/zh unknown
- 2019-07-19 AU AU2019306721A patent/AU2019306721B2/en active Active
- 2019-07-19 PE PE2021000080A patent/PE20211376A1/es unknown
- 2019-07-19 CA CA3112511A patent/CA3112511A1/en active Pending
- 2019-07-19 MX MX2021000732A patent/MX2021000732A/es unknown
- 2019-07-19 EP EP19838340.8A patent/EP3824907B1/en active Active
- 2019-07-19 BR BR112021000949-3A patent/BR112021000949A2/pt unknown
- 2019-07-19 CN CN202310983277.XA patent/CN116785439A/zh active Pending
- 2019-07-19 US US17/261,480 patent/US20210269535A1/en active Pending
-
2021
- 2021-01-18 IL IL280257A patent/IL280257A/en unknown
- 2021-01-18 PH PH12021550134A patent/PH12021550134A1/en unknown
- 2021-02-18 ZA ZA2021/01113A patent/ZA202101113B/en unknown
-
2022
- 2022-09-16 JP JP2022148180A patent/JP7475011B2/ja active Active
-
2024
- 2024-04-08 JP JP2024061895A patent/JP7703174B2/ja active Active
-
2025
- 2025-06-16 JP JP2025100449A patent/JP2025134820A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201710296A (zh) * | 2015-04-28 | 2017-03-16 | Mitsubishi Tanabe Pharma Corp | RGMa結合蛋白質及其使用 |
Non-Patent Citations (1)
| Title |
|---|
| 期刊 , MC LEVIN, et al., "Autoantibodies to heterogeneous nuclear ribonuclear protein A1 (hnRNPA1) cause altered ‘ribostasis’and neurodegeneration; the legacy of HAM/TSP as a model of progressive multiple sclerosis", Journal of Neuroimmunology, 304, ELSEVIER, 2017: 56~62. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7284557B2 (ja) | 医薬組成物 | |
| JP6875683B2 (ja) | 多発性硬化症(ms)患者の新規治療適用判断方法 | |
| JP2010100578A (ja) | Htlv−i関連脊髄症を治療または予防するための医薬、およびhtlv−i関連脊髄症の患者に対する抗体療法の効果を予測する方法 | |
| JP2024513262A (ja) | Nkp46及びcd38を標的とする二重特異性抗体、並びにその使用方法 | |
| WO2021088904A1 (zh) | 抗人程序性死亡配体-1(pd-l1)的抗体及其用途 | |
| JP2025134820A (ja) | Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法 | |
| JP2025526677A (ja) | B7-h3抗原結合性分子 | |
| WO2021062332A1 (en) | Combination of inhibitors of il4 signaling and immune checkpoints for treating cancer | |
| US20140065154A1 (en) | Tlr3 binding agents | |
| JP2024522279A (ja) | CD300c抗原またはその受容体に特異的に結合するキメラ抗原受容体 | |
| JP7818747B2 (ja) | 抗-CD300cモノクローナル抗体及びその癌の予防または治療用バイオマーカー | |
| TWI790193B (zh) | 調控免疫反應之方法及抗體 | |
| RU2833547C2 (ru) | Терапевтический или профилактический агент для htlv-1-ассоциированной миелопатии (ham) и способ лечения ham | |
| US20230242666A1 (en) | Methods and Compositions for the Reduction of Chimeric Antigen Receptor Tonic Signaling | |
| JP2018024615A (ja) | Htlv−1関連炎症性疾患を治療する医薬組成物 | |
| CN114616245A (zh) | 一种抗cd38的抗体及其用途 | |
| US9751949B2 (en) | Method of inhibiting adipogenesis with an IL-20 antibody | |
| HK40054121A (en) | Agent for treatment or prevention of htlv-1-associated myelopathy (ham), and ham treatment method | |
| KR20240082201A (ko) | B7-h3 키메라 항원 수용체 및 이의 용도 | |
| JP2024513264A (ja) | Nkp46及びgpc3を標的とする二重特異性抗体、並びにその使用方法 |